Skip to main content
Journal cover image

An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients.

Publication ,  Journal Article
Li, B; Sursal, T; Martinez, E; Karimov, Z; Feldstein, E; Stein, A; Cooper, J; Hosein-Woodley, R; Liu, A; McIntyre, M; Bowers, C; Hanft, S ...
Published in: Interv Neuroradiol
August 2023

BACKGROUND: Heparin induced thrombocytopenia Type II (HIT-II) is a dangerous thromboembolic complication of heparin therapy. The current literature on incidence and outcomes of HIT-II in aneurysmal subarachnoid hemorrhage (aSAH) patients remains sparse. OBJECTIVE: We report our institution's incidence and outcomes of HIT-II in aSAH patients. METHODS: We performed a retrospective cohort study at an academic medical center between June 2014 and July 2018. All patients had aSAH confirmed by digital subtraction angiography. Diagnosis of HIT-II was determined by positive results on both heparin PF4-platelet antibody ELISA (anti-PF4) and serotonin release assay (SRA). RESULTS: 204 patients met inclusion criteria. Seven patients (7/204, 3.5%) underwent laboratory testing, three of whom met clinical criteria. HIT-II incidence was confirmed in two of these seven patients (2/204, 0.98%), who had high BMI and T4 scores. CONCLUSION: Our institution's report of HIT-II incidence in aSAH patients is lower than previously reported in this population and more closely parallels HIT-II incidence in the general and surgical ICU setting. Widely-accepted American College of Chest Physicians (ACCP) clinical diagnostic criteria in conjunction with anti-PF4 and SRA testing is the gold standard of clinical diagnosis of HIT-II in aSAH patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Interv Neuroradiol

DOI

EISSN

2385-2011

Publication Date

August 2023

Volume

29

Issue

4

Start / End Page

363 / 370

Location

United States

Related Subject Headings

  • Thrombosis
  • Thrombocytopenia
  • Subarachnoid Hemorrhage
  • Retrospective Studies
  • Humans
  • Heparin
  • Anticoagulants
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, B., Sursal, T., Martinez, E., Karimov, Z., Feldstein, E., Stein, A., … Al-Mufti, F. (2023). An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients. Interv Neuroradiol, 29(4), 363–370. https://doi.org/10.1177/15910199221091643
Li, Boyi, Tolga Sursal, Erick Martinez, Zafar Karimov, Eric Feldstein, Alan Stein, Jared Cooper, et al. “An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients.Interv Neuroradiol 29, no. 4 (August 2023): 363–70. https://doi.org/10.1177/15910199221091643.
Li B, Sursal T, Martinez E, Karimov Z, Feldstein E, Stein A, et al. An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients. Interv Neuroradiol. 2023 Aug;29(4):363–70.
Li, Boyi, et al. “An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients.Interv Neuroradiol, vol. 29, no. 4, Aug. 2023, pp. 363–70. Pubmed, doi:10.1177/15910199221091643.
Li B, Sursal T, Martinez E, Karimov Z, Feldstein E, Stein A, Cooper J, Hosein-Woodley R, Liu A, McIntyre M, Bowers C, Hanft S, Hafeez Z, Pisapia J, Muh C, Tyagi R, Mayer SA, Gandhi CD, Al-Mufti F. An institutional report of heparin induced thrombocytopenia type II in aneurysmal subarachnoid hemorrhage patients. Interv Neuroradiol. 2023 Aug;29(4):363–370.
Journal cover image

Published In

Interv Neuroradiol

DOI

EISSN

2385-2011

Publication Date

August 2023

Volume

29

Issue

4

Start / End Page

363 / 370

Location

United States

Related Subject Headings

  • Thrombosis
  • Thrombocytopenia
  • Subarachnoid Hemorrhage
  • Retrospective Studies
  • Humans
  • Heparin
  • Anticoagulants
  • 3209 Neurosciences
  • 3202 Clinical sciences